陈群,赵艳芳,王砚青

• 1:南京中医药大学附属八一医院心内科

摘要(Abstract)：

<正>支架置入术是目前治疗冠状动脉严重狭窄性疾病的主要方法。自从2000年药物洗脱支架(drug-eluting stent,DES)首次应用于临床,其治疗冠状动脉狭窄病变的有效性和安全性已在一系列的随机对照试验和临床注册研究中得到证实。然而,支架置入术后远期发生的支架边缘再狭窄依然是临床医

关键词(KeyWords)： 药物洗脱支架;冠状动脉狭窄;支架边缘再狭窄

Abstract:

Keywords:

基金项目(Foundation): 南京军区医学科技创新课题(14ZD22)

作者(Author): 陈群,赵艳芳,王砚青

参考文献(References)：

• [1]Mehran R,Dangas G,Abizad AS,et al.Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome.Circulation,1999,100(18):1872-1878.
• [2]Stone GW,Maehara A,Lansky AJ,et al.A prospective naturalhistory study of coronary atherosclerosis.N Engl J Med,2011,364(3):226-235.
• [3]Nam CW,Rha SW,Koo BK,et al.Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis.Am J Cardiol,2011,107(12):1783-1786.
• [4]罗明华,王贺,关怀敏.支架内新生动脉粥样硬化进展研究.中国循环杂志,2014,29(10):848-851.
• [5]Weissman NJ,Wilensky RL,Tanguay JF,et al.Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population.Am J Cardiol,2001,88(3):248-252.
• [6]Weissman NJ,Koglin J,Cox DA,et al.Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation:a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.J Am Coll Cardiol,2005,45(8):1201-1205.
• [7]Weissman NJ,Ellis SG,Grube E,et al.Effect of the polymerbased,paclitaxel-eluting TAXUS Express stent on vascular tissue responses:a volumetric intravascular ultrasound integrated analysis from the TAXUS IV,V,and VI trials.Eur Heart J,2007,28(13):1574-1582.
• [8]Kang WC,Park YM,Shin KC,et al.Predictors of edge stenosis after paclitaxel-eluting stent implantation.Coron Artery Dis,2011,22(1):59-63.
• [9]Corbett SJ,Cosgrave J,Melzi G,et al.Patterns of restenosis after drug-eluting stent implantation:insights from a contemporary and comparative analysis of sirolimus-and paclitaxel-eluting stents.Eur Heart J,2006,27(19):2330-2337.
• [10]Ichimoto E,Fujimoto Y,Kubo K,et al.Mechanism of edge restenosis after sirolimus-eluting stent implantation.J Invasive Cardiol,2012,24(2):55-57.
• [11]李少君,李宁,李志韬,等.球囊过盈量与支架术后边缘效应的关系探讨.北京生物医学工程,2010,29(4):384-387.
• [12]Sun A,Wang Z,Fan Z,et al.Influence of proximal drug eluting stent(DES)on distal bare metal stent(BMS)in multi-stent implantation strategies in coronary arteries.Med Eng Phys,2015,37(9):840-844.
• [13]Kim YG,Oh IY,Kwon YW,et al.Mechanism of edge restenosis after drug-eluting stent implantation.Angulation at the edge and mechanical properties of the stent.Circ J,2013,77(12):2928-2935.
• [14]Jensen LO,Maeng M,Mintz GS,et al.Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus.Am J Cardiol,2009,103(8):1083-1088.
• [15]刘博,张新禄,侯玉清,等.糖尿病与非糖尿病患者支架植入术后支架边缘血管形态学比较.广东医学,2014,35(7):1002-1005.
• [16]Sahara M,Kirigaya H,Oikawa Y,et al.Soft plaque detected on intravascular ultrasound is the strongest predictor of in-stent restenosis:an intravascular ultrasound study.Eur Heart J,2004,25(22):2026-2033.
• [17]Hong YJ,Jeong MH,Lim SY,et al.Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting.Am J Cardiol,2006,98(3):341-345.
• [18]Hoffmann R,Minta GS,Mehran R,et al.Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents.J Am Coll Cardiol,1998,31(1):43-49.
• [19]Prati F,Di Mario C,Moussa I,et al.In-stent neointimal proliferation correlates with the amout of residual plaque burden outside the stent:an intravascular ultrasound study.Circulation,1999,99(8):1011-1014.
• [20]Kang SJ,Cho YR,Park GM,et al.Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation.Am J Cardiol,2013,111(10):1408-1414.
• [21]Takahashi M,Miyazaki S,Myojo M,et al.Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation.PLo S One,2015,10(3):e0121079.
• [22]Piccolo R,Galasso G,Piscione F,et al.Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis.Am J Cardiol,2014,114(9):1339-1346.
• [23]Song HG,Park DW,Kim YH,et al.Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.J Am Coll Cardiol,2012,59(12):1093-1100.
• [24]Yamashika K,Ochiai M,Yakushiji T,et al.Repeat drug-eluting stent implantation for in-stent restenosis:first-or secondgeneration stent.J Invasive Cardiol,2012,24(11):574-578.
• [25]Alfonso F,Perez-Vizcayno MJ,Dutary J,et al.Implantation of a drug-eluting stent with a different drug(switch strategy)in patients with drug-eluting stent restenosis.Results from a prospective multicenter study(RIBSⅢ[Restenosis Intra-Stent:Balloon Angioplasty Versus Drug-Eluting Stent]).JACC Cardiovasc Interv,2012,5(7):728-737.
• [26]Kolh P,Windecker S,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:the Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS).Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur J Cardiothorac Surg,2014,46(4):517-592.
• [27]Xu B,Gao R,Wang J,et al.A prospective,multicenter,randomized trial of paclitaxel-coated balloon versus paclitaxeleluting stent for the treatment of drug-eluting stent in-stent restenosis:results from the PEPCAD China ISR trial.JACC Cardiovasc Interv,2014,7(2):204-211.